factuality_value
stringclasses 7
values | predicat@xml:space
stringclasses 1
value | predicat@charOffset
stringlengths 3
9
| predicat@headOffset
stringlengths 3
9
| predicat@id
stringclasses 206
values | predicat@text
stringlengths 2
124
| predicat@type
stringclasses 29
values | predicat@charOffsetMin
int64 0
3.96k
| predicat@charOffsetMax
int64 6
3.97k
| subject@xml:space
stringclasses 1
value | subject@charOffset
stringlengths 3
9
| subject@headOffset
stringlengths 3
9
| subject@id
stringclasses 197
values | subject@text
stringlengths 2
49
| subject@type
stringclasses 72
values | subject@charOffsetMin
int64 0
3.98k
| subject@charOffsetMax
int64 3
4k
| object@xml:space
stringclasses 1
value | object@charOffset
stringlengths 3
9
| object@headOffset
stringlengths 3
9
| object@id
stringclasses 198
values | object@text
stringlengths 2
53
| object@type
stringclasses 73
values | object@charOffsetMin
int64 0
3.93k
| object@charOffsetMax
int64 4
3.94k
| id
stringclasses 58
values | raw_sent_text
stringlengths 20
749
| sent_charOffset
stringlengths 4
9
| sent_charOffsetMin
int64 0
3.88k
| sent_charOffsetMax
int64 26
4.2k
| formated_sentence
stringlengths 34
768
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Fact | preserve | 788-791 | 788-791 | T51 | GBT | ISA | 788 | 791 | preserve | 788-791 | 788-791 | T50 | GBT | TherapeuticOrPreventiveProcedure | 788 | 791 | preserve | 788-791 | 788-791 | T50 | GBT | TherapeuticOrPreventiveProcedure | 788 | 791 | A1 | In 15 patients (7 female and 8 male), median age 38.8 years (range 17-54), who had been selected as suitable candidates for bariatric surgery, preoperative GBT was studied. | 620-804 | 620 | 804 | In 15 patients (7 female and 8 male), median age 38.8 years (range 17-54), who had been selected as suitable candidates for bariatric surgery, preoperative @OBJECT$ @SUBJECT$ @PREDICAT$ was studied. |
Fact | preserve | 1233-1236 | 1233-1236 | T83 | GBT | USES | 1,233 | 1,236 | preserve | 1233-1236 | 1233-1236 | T80 | GBT | TherapeuticOrPreventiveProcedure | 1,233 | 1,236 | preserve | 1233-1236 | 1233-1236 | T80 | GBT | TherapeuticOrPreventiveProcedure | 1,233 | 1,236 | A2 | RESULTS: In 14 of 15 cases, GBT was successful. | 1205-1252 | 1,205 | 1,252 | RESULTS: In 14 of 15 cases, @OBJECT$ @SUBJECT$ @PREDICAT$ was successful. |
Fact | preserve | 373-396 | 389-396 | T33 | gastric balloon therapy | USES | 373 | 396 | preserve | 389-396 | 389-396 | T27 | therapy | TherapeuticOrPreventiveProcedure | 389 | 396 | preserve | 373-388 | 381-388 | T26 | gastric balloon | MedicalDevice | 373 | 388 | A5 | The purpose of this study was to evaluate whether gastric balloon therapy (GBT) can improve the operative conditions for laparoscopic adjustable gastric banding (LAGB) in extremely obese patients. | 317-532 | 317 | 532 | The purpose of this study was to evaluate whether @OBJECT$ @PREDICAT$ @SUBJECT$ (GBT) can improve the operative conditions for laparoscopic adjustable gastric banding (LAGB) in extremely obese patients. |
Fact | preserve | 1834-1837 | 1834-1837 | T115 | GBT | ISA | 1,834 | 1,837 | preserve | 1834-1837 | 1834-1837 | T113 | GBT | TherapeuticOrPreventiveProcedure | 1,834 | 1,837 | preserve | 1834-1837 | 1834-1837 | T113 | GBT | TherapeuticOrPreventiveProcedure | 1,834 | 1,837 | A6 | However, after failure of all conservative treatments to reduce the preoperative body weight, the GBT seems to be the last possibility. | 1730-1877 | 1,730 | 1,877 | However, after failure of all conservative treatments to reduce the preoperative body weight, the @OBJECT$ @SUBJECT$ @PREDICAT$ seems to be the last possibility. |
Fact | preserve | 73-75 | 73-75 | T11 | by | METHOD_OF | 73 | 75 | preserve | 98-105 | 98-105 | T7 | therapy | TherapeuticOrPreventiveProcedure | 98 | 105 | preserve | 57-72 | 65-72 | T5 | gastric banding | TherapeuticOrPreventiveProcedure | 57 | 72 | A9 | Preparation of extremely obese patients for laparoscopic gastric banding by gastric-balloon therapy. | 0-106 | 0 | 106 | Preparation of extremely obese patients for laparoscopic @OBJECT$ @PREDICAT$ gastric-balloon @SUBJECT$ . |
Fact | preserve | 497-499 | 497-499 | T36 | in | TREATS | 497 | 499 | preserve | 450-489 | 482-489 | T29 | laparoscopic adjustable gastric banding | TherapeuticOrPreventiveProcedure | 450 | 489 | preserve | 523-531 | 523-531 | T31 | patients | PatientOrDisabledGroup | 523 | 531 | A10 | The purpose of this study was to evaluate whether gastric balloon therapy (GBT) can improve the operative conditions for laparoscopic adjustable gastric banding (LAGB) in extremely obese patients. | 317-532 | 317 | 532 | The purpose of this study was to evaluate whether gastric balloon therapy (GBT) can improve the operative conditions for @SUBJECT$ (LAGB) @PREDICAT$ extremely obese @OBJECT$ . |
Fact | preserve | 1132-1134 | 1132-1134 | T72 | in | TREATS | 1,132 | 1,134 | preserve | 1109-1118 | 1109-1118 | T69 | follow-up | HealthCareActivity | 1,109 | 1,118 | preserve | 1138-1146 | 1138-1146 | T71 | patients | PatientOrDisabledGroup | 1,138 | 1,146 | A11 | Close follow-up was possible in 14 patients. | 1097-1147 | 1,097 | 1,147 | Close @SUBJECT$ was possible @PREDICAT$ 14 @OBJECT$ . |
Fact | preserve | 373-396 | 389-396 | T32 | gastric balloon therapy | ISA | 373 | 396 | preserve | 373-388 | 381-388 | T26 | gastric balloon | MedicalDevice | 373 | 388 | preserve | 389-396 | 389-396 | T27 | therapy | TherapeuticOrPreventiveProcedure | 389 | 396 | A12 | The purpose of this study was to evaluate whether gastric balloon therapy (GBT) can improve the operative conditions for laparoscopic adjustable gastric banding (LAGB) in extremely obese patients. | 317-532 | 317 | 532 | The purpose of this study was to evaluate whether @SUBJECT$ @PREDICAT$ @OBJECT$ (GBT) can improve the operative conditions for laparoscopic adjustable gastric banding (LAGB) in extremely obese patients. |
Fact | preserve | 82-105 | 98-105 | T13 | gastric-balloon therapy | METHOD_OF | 82 | 105 | preserve | 82-97 | 82-97 | T6 | gastric-balloon | MedicalDevice | 82 | 97 | preserve | 57-72 | 65-72 | T5 | gastric banding | TherapeuticOrPreventiveProcedure | 57 | 72 | A13 | Preparation of extremely obese patients for laparoscopic gastric banding by gastric-balloon therapy. | 0-106 | 0 | 106 | Preparation of extremely obese patients for laparoscopic @OBJECT$ by @SUBJECT$ @PREDICAT$ . |
Fact | preserve | 25-39 | 31-39 | T9 | obese patients | PROCESS_OF | 25 | 39 | preserve | 25-30 | 25-30 | T2 | obese | DiseaseOrSyndrome | 25 | 30 | preserve | 31-39 | 31-39 | T3 | patients | PatientOrDisabledGroup | 31 | 39 | A14 | Preparation of extremely obese patients for laparoscopic gastric banding by gastric-balloon therapy. | 0-106 | 0 | 106 | Preparation of extremely @SUBJECT$ @PREDICAT$ @OBJECT$ for laparoscopic gastric banding by gastric-balloon therapy. |
Fact | preserve | 1545-1548 | 1545-1548 | T102 | for | USES | 1,545 | 1,548 | preserve | 1549-1569 | 1562-1569 | T97 | laparoscopic surgery | TherapeuticOrPreventiveProcedure | 1,549 | 1,569 | preserve | 1496-1511 | 1504-1511 | T95 | gastric balloon | MedicalDevice | 1,496 | 1,511 | A15 | CONCLUSIONS: In our experience, the gastric balloon can improve the conditions for laparoscopic surgery in super and in super, super obese patients. | 1460-1614 | 1,460 | 1,614 | CONCLUSIONS: In our experience, the @OBJECT$ can improve the conditions @PREDICAT$ @SUBJECT$ in super and in super, super obese patients. |
Fact | preserve | 1233-1236 | 1233-1236 | T82 | GBT | ISA | 1,233 | 1,236 | preserve | 1233-1236 | 1233-1236 | T80 | GBT | TherapeuticOrPreventiveProcedure | 1,233 | 1,236 | preserve | 1233-1236 | 1233-1236 | T80 | GBT | TherapeuticOrPreventiveProcedure | 1,233 | 1,236 | A16 | RESULTS: In 14 of 15 cases, GBT was successful. | 1205-1252 | 1,205 | 1,252 | RESULTS: In 14 of 15 cases, @OBJECT$ @SUBJECT$ @PREDICAT$ was successful. |
Fact | preserve | 82-105 | 98-105 | T8 | gastric-balloon therapy | ISA | 82 | 105 | preserve | 82-97 | 82-97 | T6 | gastric-balloon | MedicalDevice | 82 | 97 | preserve | 98-105 | 98-105 | T7 | therapy | TherapeuticOrPreventiveProcedure | 98 | 105 | A18 | Preparation of extremely obese patients for laparoscopic gastric banding by gastric-balloon therapy. | 0-106 | 0 | 106 | Preparation of extremely obese patients for laparoscopic gastric banding by @SUBJECT$ @PREDICAT$ @OBJECT$ . |
Fact | preserve | 497-499 | 497-499 | T36 | in | TREATS | 497 | 499 | preserve | 450-489 | 482-489 | T29 | laparoscopic adjustable gastric banding | TherapeuticOrPreventiveProcedure | 450 | 489 | preserve | 510-515 | 510-515 | T30 | obese | DiseaseOrSyndrome | 510 | 515 | A19 | The purpose of this study was to evaluate whether gastric balloon therapy (GBT) can improve the operative conditions for laparoscopic adjustable gastric banding (LAGB) in extremely obese patients. | 317-532 | 317 | 532 | The purpose of this study was to evaluate whether gastric balloon therapy (GBT) can improve the operative conditions for @SUBJECT$ (LAGB) @PREDICAT$ extremely @OBJECT$ patients. |
Fact | preserve | 82-105 | 98-105 | T10 | gastric-balloon therapy | USES | 82 | 105 | preserve | 98-105 | 98-105 | T7 | therapy | TherapeuticOrPreventiveProcedure | 98 | 105 | preserve | 82-97 | 82-97 | T6 | gastric-balloon | MedicalDevice | 82 | 97 | A20 | Preparation of extremely obese patients for laparoscopic gastric banding by gastric-balloon therapy. | 0-106 | 0 | 106 | Preparation of extremely obese patients for laparoscopic gastric banding by @OBJECT$ @PREDICAT$ @SUBJECT$ . |
Fact | preserve | 1834-1837 | 1834-1837 | T116 | GBT | USES | 1,834 | 1,837 | preserve | 1834-1837 | 1834-1837 | T113 | GBT | TherapeuticOrPreventiveProcedure | 1,834 | 1,837 | preserve | 1834-1837 | 1834-1837 | T113 | GBT | TherapeuticOrPreventiveProcedure | 1,834 | 1,837 | A21 | However, after failure of all conservative treatments to reduce the preoperative body weight, the GBT seems to be the last possibility. | 1730-1877 | 1,730 | 1,877 | However, after failure of all conservative treatments to reduce the preoperative body weight, the @OBJECT$ @SUBJECT$ @PREDICAT$ seems to be the last possibility. |
Fact | preserve | 510-531 | 523-531 | T35 | obese patients | PROCESS_OF | 510 | 531 | preserve | 510-515 | 510-515 | T30 | obese | DiseaseOrSyndrome | 510 | 515 | preserve | 523-531 | 523-531 | T31 | patients | PatientOrDisabledGroup | 523 | 531 | A23 | The purpose of this study was to evaluate whether gastric balloon therapy (GBT) can improve the operative conditions for laparoscopic adjustable gastric banding (LAGB) in extremely obese patients. | 317-532 | 317 | 532 | The purpose of this study was to evaluate whether gastric balloon therapy (GBT) can improve the operative conditions for laparoscopic adjustable gastric banding (LAGB) in extremely @SUBJECT$ @PREDICAT$ @OBJECT$ . |
Fact | preserve | 1189-1198 | 1189-1198 | T76 | underwent | TREATS | 1,189 | 1,198 | preserve | 1199-1203 | 1199-1203 | T75 | LAGB | TherapeuticOrPreventiveProcedure | 1,199 | 1,203 | preserve | 1174-1182 | 1174-1182 | T74 | patients | PatientOrDisabledGroup | 1,174 | 1,182 | A25 | After balloon removal, 13 patients underwent LAGB. | 1148-1204 | 1,148 | 1,204 | After balloon removal, 13 @OBJECT$ @PREDICAT$ @SUBJECT$ . |
Fact | preserve | 788-791 | 788-791 | T52 | GBT | USES | 788 | 791 | preserve | 788-791 | 788-791 | T50 | GBT | TherapeuticOrPreventiveProcedure | 788 | 791 | preserve | 788-791 | 788-791 | T50 | GBT | TherapeuticOrPreventiveProcedure | 788 | 791 | A26 | In 15 patients (7 female and 8 male), median age 38.8 years (range 17-54), who had been selected as suitable candidates for bariatric surgery, preoperative GBT was studied. | 620-804 | 620 | 804 | In 15 patients (7 female and 8 male), median age 38.8 years (range 17-54), who had been selected as suitable candidates for bariatric surgery, preoperative @OBJECT$ @SUBJECT$ @PREDICAT$ was studied. |
Fact | preserve | 1166-1225 | 1186-1190 | T54 | surgical procedures such as coronary artery bypass grafting | ISA | 1,166 | 1,225 | preserve | 1277-1287 | 1277-1287 | T52 | insertions | TherapeuticOrPreventiveProcedure | 1,277 | 1,287 | preserve | 1166-1185 | 1175-1185 | T48 | surgical procedures | TherapeuticOrPreventiveProcedure | 1,166 | 1,185 | A10 | After comparing the short-term outcomes predicted for the 4S with the results actually observed, we forecast the long-term risk of recurrent myocardial infarction, congestive heart failure, transient ischemic attacks, arrhythmias, and strokes and the need for surgical procedures such as coronary artery bypass grafting, catheterization, angioplasty, and pacemaker insertions. | 881-1288 | 881 | 1,288 | After comparing the short-term outcomes predicted for the 4S with the results actually observed, we forecast the long-term risk of recurrent myocardial infarction, congestive heart failure, transient ischemic attacks, arrhythmias, and strokes and the need for @OBJECT$ @PREDICAT$ , catheterization, angioplasty, and pacemaker @SUBJECT$ . |
Fact | preserve | 1166-1225 | 1186-1190 | T54 | surgical procedures such as coronary artery bypass grafting | ISA | 1,166 | 1,225 | preserve | 1227-1242 | 1227-1242 | T50 | catheterization | TherapeuticOrPreventiveProcedure | 1,227 | 1,242 | preserve | 1166-1185 | 1175-1185 | T48 | surgical procedures | TherapeuticOrPreventiveProcedure | 1,166 | 1,185 | A13 | After comparing the short-term outcomes predicted for the 4S with the results actually observed, we forecast the long-term risk of recurrent myocardial infarction, congestive heart failure, transient ischemic attacks, arrhythmias, and strokes and the need for surgical procedures such as coronary artery bypass grafting, catheterization, angioplasty, and pacemaker insertions. | 881-1288 | 881 | 1,288 | After comparing the short-term outcomes predicted for the 4S with the results actually observed, we forecast the long-term risk of recurrent myocardial infarction, congestive heart failure, transient ischemic attacks, arrhythmias, and strokes and the need for @OBJECT$ @PREDICAT$ , @SUBJECT$ , angioplasty, and pacemaker insertions. |
Fact | preserve | 887-896 | 887-896 | T53 | comparing | compared_with | 887 | 896 | preserve | 1250-1261 | 1250-1261 | T51 | angioplasty | TherapeuticOrPreventiveProcedure | 1,250 | 1,261 | preserve | 1277-1287 | 1277-1287 | T52 | insertions | TherapeuticOrPreventiveProcedure | 1,277 | 1,287 | A14 | After comparing the short-term outcomes predicted for the 4S with the results actually observed, we forecast the long-term risk of recurrent myocardial infarction, congestive heart failure, transient ischemic attacks, arrhythmias, and strokes and the need for surgical procedures such as coronary artery bypass grafting, catheterization, angioplasty, and pacemaker insertions. | 881-1288 | 881 | 1,288 | After @PREDICAT$ the short-term outcomes predicted for the 4S with the results actually observed, we forecast the long-term risk of recurrent myocardial infarction, congestive heart failure, transient ischemic attacks, arrhythmias, and strokes and the need for surgical procedures such as coronary artery bypass grafting, catheterization, @SUBJECT$ , and pacemaker @OBJECT$ . |
Fact | preserve | 812-820 | 812-820 | T35 | increase | STIMULATES | 812 | 820 | preserve | 632-639 | 632-639 | T23 | statins | OrganicChemical | 632 | 639 | preserve | 830-854 | 830-854 | T32 | high-density-lipoprotein | AminoAcidPeptideOrProtein | 830 | 854 | A18 | METHODS: A validated model based on data from the Lipid Research Clinics cohort was used to estimate the benefits and cost-effectiveness of lipid modification with 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) based on results from the Scandinavian Simvastatin Survival Study (4S), including a 35% decrease in low-density-lipoprotein (LDL)-cholesterol levels and an 8% increase in high-density-lipoprotein (HDL)-cholesterol levels. | 389-880 | 389 | 880 | METHODS: A validated model based on data from the Lipid Research Clinics cohort was used to estimate the benefits and cost-effectiveness of lipid modification with 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors ( @SUBJECT$ ) based on results from the Scandinavian Simvastatin Survival Study (4S), including a 35% decrease in low-density-lipoprotein (LDL)-cholesterol levels and an 8% @PREDICAT$ in @OBJECT$ (HDL)-cholesterol levels. |
Fact | preserve | 1166-1225 | 1186-1190 | T54 | surgical procedures such as coronary artery bypass grafting | ISA | 1,166 | 1,225 | preserve | 1194-1225 | 1217-1225 | T49 | coronary artery bypass grafting | TherapeuticOrPreventiveProcedure | 1,194 | 1,225 | preserve | 1166-1185 | 1175-1185 | T48 | surgical procedures | TherapeuticOrPreventiveProcedure | 1,166 | 1,185 | A20 | After comparing the short-term outcomes predicted for the 4S with the results actually observed, we forecast the long-term risk of recurrent myocardial infarction, congestive heart failure, transient ischemic attacks, arrhythmias, and strokes and the need for surgical procedures such as coronary artery bypass grafting, catheterization, angioplasty, and pacemaker insertions. | 881-1288 | 881 | 1,288 | After comparing the short-term outcomes predicted for the 4S with the results actually observed, we forecast the long-term risk of recurrent myocardial infarction, congestive heart failure, transient ischemic attacks, arrhythmias, and strokes and the need for @OBJECT$ @PREDICAT$ @SUBJECT$ , catheterization, angioplasty, and pacemaker insertions. |
Fact | preserve | 1166-1225 | 1186-1190 | T54 | surgical procedures such as coronary artery bypass grafting | ISA | 1,166 | 1,225 | preserve | 1250-1261 | 1250-1261 | T51 | angioplasty | TherapeuticOrPreventiveProcedure | 1,250 | 1,261 | preserve | 1166-1185 | 1175-1185 | T48 | surgical procedures | TherapeuticOrPreventiveProcedure | 1,166 | 1,185 | A24 | After comparing the short-term outcomes predicted for the 4S with the results actually observed, we forecast the long-term risk of recurrent myocardial infarction, congestive heart failure, transient ischemic attacks, arrhythmias, and strokes and the need for surgical procedures such as coronary artery bypass grafting, catheterization, angioplasty, and pacemaker insertions. | 881-1288 | 881 | 1,288 | After comparing the short-term outcomes predicted for the 4S with the results actually observed, we forecast the long-term risk of recurrent myocardial infarction, congestive heart failure, transient ischemic attacks, arrhythmias, and strokes and the need for @OBJECT$ @PREDICAT$ , catheterization, @SUBJECT$ , and pacemaker insertions. |
Fact | preserve | 1765-1773 | 1765-1773 | T118 | increase | AUGMENTS | 1,765 | 1,773 | preserve | 1729-1738 | 1729-1738 | T109 | tamoxifen | OrganicChemical | 1,729 | 1,738 | preserve | 1777-1796 | 1789-1796 | T112 | endometrial cancers | NeoplasticProcess | 1,777 | 1,796 | A1 | We cannot be certain of the mode of action of tamoxifen that results in the increase in endometrial cancers in treated women but it seems unlikely that this will be associated with a classical genotoxic mechanism. | 1683-1909 | 1,683 | 1,909 | We cannot be certain of the mode of action of @SUBJECT$ that results in the @PREDICAT$ in @OBJECT$ in treated women but it seems unlikely that this will be associated with a classical genotoxic mechanism. |
Fact | preserve | 1492-1494 | 1492-1494 | T105 | in | PROCESS_OF | 1,492 | 1,494 | preserve | 1471-1491 | 1477-1491 | T91 | liver carcinogenesis | NeoplasticProcess | 1,471 | 1,491 | preserve | 1499-1502 | 1499-1502 | T92 | rat | Mammal | 1,499 | 1,502 | A2 | Based on a mechanistic understanding of tamoxifen-induced liver carcinogenesis in the rat, it seems that in humans hepatic DNA damage will be close to the limit of detection by 32P-post-labelling and liver cancer will not be a significant carcinogenic risk. | 1407-1682 | 1,407 | 1,682 | Based on a mechanistic understanding of tamoxifen-induced @SUBJECT$ @PREDICAT$ the @OBJECT$ , it seems that in humans hepatic DNA damage will be close to the limit of detection by 32P-post-labelling and liver cancer will not be a significant carcinogenic risk. |
Fact | preserve | 505-507 | 505-507 | T44 | in | TREATS | 505 | 507 | preserve | 495-504 | 495-504 | T33 | tamoxifen | OrganicChemical | 495 | 504 | preserve | 508-521 | 515-521 | T34 | breast cancer | NeoplasticProcess | 508 | 521 | A3 | While the use of tamoxifen in breast cancer patients is clearly justified, the situation for its use as a chemopreventive agent in healthy women is not so clear cut. | 478-655 | 478 | 655 | While the use of @SUBJECT$ @PREDICAT$ @OBJECT$ patients is clearly justified, the situation for its use as a chemopreventive agent in healthy women is not so clear cut. |
Fact | preserve | 758-774 | 764-774 | T54 | liver carcinogen | LOCATION_OF | 758 | 774 | preserve | 758-763 | 758-763 | T52 | liver | BodyPartOrganOrOrganComponent | 758 | 763 | preserve | 764-774 | 764-774 | T53 | carcinogen | HazardousOrPoisonousSubstance | 764 | 774 | A4 | Reasons for caution come from studies in rats that show that tamoxifen is a genotoxic mutagenic liver carcinogen. | 656-775 | 656 | 775 | Reasons for caution come from studies in rats that show that tamoxifen is a genotoxic mutagenic @SUBJECT$ @PREDICAT$ @OBJECT$ . |
Fact | preserve | 1069-1098 | 1086-1098 | T74 | accelerator mass spectrometry | USES | 1,069 | 1,098 | preserve | 1081-1098 | 1086-1098 | T71 | mass spectrometry | LaboratoryProcedure | 1,081 | 1,098 | preserve | 1069-1080 | 1069-1080 | T70 | accelerator | ManufacturedObject | 1,069 | 1,080 | A5 | The extent of DNA damage, detected by 32P-post-labelling or accelerator mass spectrometry, is dependent both on the dose and the length of exposure. | 1003-1163 | 1,003 | 1,163 | The extent of DNA damage, detected by 32P-post-labelling or @OBJECT$ @PREDICAT$ @SUBJECT$ , is dependent both on the dose and the length of exposure. |
Fact | preserve | 120-124 | 120-124 | T15 | with | PROCESS_OF | 120 | 124 | preserve | 125-138 | 132-138 | T7 | breast cancer | NeoplasticProcess | 125 | 138 | preserve | 114-119 | 114-119 | T6 | women | PopulationGroup | 114 | 119 | A6 | The anti-oestrogen tamoxifen is widely used for adjuvant therapy in the treatment of women with breast cancer and has a low incidence of serious side-effects. | 23-187 | 23 | 187 | The anti-oestrogen tamoxifen is widely used for adjuvant therapy in the treatment of @OBJECT$ @PREDICAT$ @SUBJECT$ and has a low incidence of serious side-effects. |
Fact | preserve | 505-507 | 505-507 | T44 | in | TREATS | 505 | 507 | preserve | 495-504 | 495-504 | T33 | tamoxifen | OrganicChemical | 495 | 504 | preserve | 528-536 | 528-536 | T35 | patients | PatientOrDisabledGroup | 528 | 536 | A7 | While the use of tamoxifen in breast cancer patients is clearly justified, the situation for its use as a chemopreventive agent in healthy women is not so clear cut. | 478-655 | 478 | 655 | While the use of @SUBJECT$ @PREDICAT$ breast cancer @OBJECT$ is clearly justified, the situation for its use as a chemopreventive agent in healthy women is not so clear cut. |
Fact | preserve | 508-536 | 528-536 | T43 | breast cancer patients | PROCESS_OF | 508 | 536 | preserve | 508-521 | 515-521 | T34 | breast cancer | NeoplasticProcess | 508 | 521 | preserve | 528-536 | 528-536 | T35 | patients | PatientOrDisabledGroup | 528 | 536 | A8 | While the use of tamoxifen in breast cancer patients is clearly justified, the situation for its use as a chemopreventive agent in healthy women is not so clear cut. | 478-655 | 478 | 655 | While the use of tamoxifen in @SUBJECT$ @PREDICAT$ @OBJECT$ is clearly justified, the situation for its use as a chemopreventive agent in healthy women is not so clear cut. |
Fact | preserve | 42-104 | 62-66 | T13 | tamoxifen is widely used for adjuvant therapy in the treatment | ISA | 42 | 104 | preserve | 42-51 | 42-51 | T3 | tamoxifen | OrganicChemical | 42 | 51 | preserve | 95-104 | 95-104 | T5 | treatment | TherapeuticOrPreventiveProcedure | 95 | 104 | A9 | The anti-oestrogen tamoxifen is widely used for adjuvant therapy in the treatment of women with breast cancer and has a low incidence of serious side-effects. | 23-187 | 23 | 187 | The anti-oestrogen @SUBJECT$ @PREDICAT$ @OBJECT$ of women with breast cancer and has a low incidence of serious side-effects. |
Fact | preserve | 1238-1257 | 1246-1257 | T82 | uterine endometrium | PART_OF | 1,238 | 1,257 | preserve | 1246-1257 | 1246-1257 | T78 | endometrium | BodyPartOrganOrOrganComponent | 1,246 | 1,257 | preserve | 1238-1245 | 1238-1245 | T77 | uterine | BodyPartOrganOrOrganComponent | 1,238 | 1,245 | A10 | Studies have been carried out to see if such binding occurs in the uterine endometrium from tamoxifen-treated women. | 1164-1293 | 1,164 | 1,293 | Studies have been carried out to see if such binding occurs in the @OBJECT$ @PREDICAT$ @SUBJECT$ from tamoxifen-treated women. |
Fact | preserve | 27-51 | 42-51 | T12 | anti-oestrogen tamoxifen | ISA | 27 | 51 | preserve | 42-51 | 42-51 | T3 | tamoxifen | OrganicChemical | 42 | 51 | preserve | 27-41 | 27-41 | T2 | anti-oestrogen | PharmacologicSubstance | 27 | 41 | A12 | The anti-oestrogen tamoxifen is widely used for adjuvant therapy in the treatment of women with breast cancer and has a low incidence of serious side-effects. | 23-187 | 23 | 187 | The @OBJECT$ @PREDICAT$ @SUBJECT$ is widely used for adjuvant therapy in the treatment of women with breast cancer and has a low incidence of serious side-effects. |
Fact | preserve | 67-70 | 67-70 | T14 | for | USES | 67 | 70 | preserve | 71-87 | 80-87 | T4 | adjuvant therapy | TherapeuticOrPreventiveProcedure | 71 | 87 | preserve | 42-51 | 42-51 | T3 | tamoxifen | OrganicChemical | 42 | 51 | A13 | The anti-oestrogen tamoxifen is widely used for adjuvant therapy in the treatment of women with breast cancer and has a low incidence of serious side-effects. | 23-187 | 23 | 187 | The anti-oestrogen @OBJECT$ is widely used @PREDICAT$ @SUBJECT$ in the treatment of women with breast cancer and has a low incidence of serious side-effects. |
Fact | preserve | 798-800 | 798-800 | T63 | in | PROCESS_OF | 798 | 800 | preserve | 790-797 | 790-797 | T55 | tumours | NeoplasticProcess | 790 | 797 | preserve | 805-808 | 805-808 | T56 | rat | Mammal | 805 | 808 | A14 | Initiation of tumours in the rat is the result of metabolic activation of tamoxifen by CYP enzymes to an electrophile(s) that binds irreversibly to DNA. | 776-934 | 776 | 934 | Initiation of @SUBJECT$ @PREDICAT$ the @OBJECT$ is the result of metabolic activation of tamoxifen by CYP enzymes to an electrophile(s) that binds irreversibly to DNA. |
Fact | preserve | 1797-1799 | 1797-1799 | T119 | in | PROCESS_OF | 1,797 | 1,799 | preserve | 1777-1796 | 1789-1796 | T112 | endometrial cancers | NeoplasticProcess | 1,777 | 1,796 | preserve | 1808-1813 | 1808-1813 | T114 | women | PopulationGroup | 1,808 | 1,813 | A16 | We cannot be certain of the mode of action of tamoxifen that results in the increase in endometrial cancers in treated women but it seems unlikely that this will be associated with a classical genotoxic mechanism. | 1683-1909 | 1,683 | 1,909 | We cannot be certain of the mode of action of tamoxifen that results in the increase in @SUBJECT$ @PREDICAT$ treated @OBJECT$ but it seems unlikely that this will be associated with a classical genotoxic mechanism. |
Fact | preserve | 1682-1686 | 1682-1686 | T85 | with | PROCESS_OF | 1,682 | 1,686 | preserve | 1702-1715 | 1709-1715 | T82 | mental status | Finding | 1,702 | 1,715 | preserve | 1673-1681 | 1673-1681 | T80 | patients | PatientOrDisabledGroup | 1,673 | 1,681 | A1 | We concluded that: 1) age is a critical factor to determine the rehabilitation outcome, but may not be an important factor to predict the ability for the improvement through rehabilitation therapy; 2) the delay of rehabilitation therapy may not affect the potential for further improvement; 3) patients with low initial functional level may have poor final outcome, they may still have good rehabilitation potential to improve the functional level; 4) complications of stroke may affect the rehabilitation outcome and should be prevented; and 5) patients with impaired mental status should not routinely be excluded from rehabilitation programs. | 1084-1778 | 1,084 | 1,778 | We concluded that: 1) age is a critical factor to determine the rehabilitation outcome, but may not be an important factor to predict the ability for the improvement through rehabilitation therapy; 2) the delay of rehabilitation therapy may not affect the potential for further improvement; 3) patients with low initial functional level may have poor final outcome, they may still have good rehabilitation potential to improve the functional level; 4) complications of stroke may affect the rehabilitation outcome and should be prevented; and 5) @OBJECT$ @PREDICAT$ impaired @SUBJECT$ should not routinely be excluded from rehabilitation programs. |
Fact | preserve | 229-244 | 236-244 | T14 | stroke patients | PROCESS_OF | 229 | 244 | preserve | 229-235 | 229-235 | T12 | stroke | DiseaseOrSyndrome | 229 | 235 | preserve | 236-244 | 236-244 | T13 | patients | PatientOrDisabledGroup | 236 | 244 | A2 | The purpose of this prospective study was to investigate the influence of rehabilitation therapy on the prognosis for stroke patients. | 105-245 | 105 | 245 | The purpose of this prospective study was to investigate the influence of rehabilitation therapy on the prognosis for @SUBJECT$ @PREDICAT$ @OBJECT$ . |
Fact | preserve | 324-339 | 331-339 | T27 | stroke patients | PROCESS_OF | 324 | 339 | preserve | 324-330 | 324-330 | T19 | stroke | DiseaseOrSyndrome | 324 | 330 | preserve | 331-339 | 331-339 | T20 | patients | PatientOrDisabledGroup | 331 | 339 | A3 | Sociodemographic and clinical factors were collected in a sample of 147 stroke patients (81 men and 66 women) admitted to the inpatient rehabilitation department at our university hospital over 10 days between January 1, 1997 and December 31, 1997. | 246-512 | 246 | 512 | Sociodemographic and clinical factors were collected in a sample of 147 @SUBJECT$ @PREDICAT$ @OBJECT$ (81 men and 66 women) admitted to the inpatient rehabilitation department at our university hospital over 10 days between January 1, 1997 and December 31, 1997. |
Uncommitted | preserve | 225-228 | 225-228 | T15 | for | TREATS | 225 | 228 | preserve | 185-207 | 200-207 | T11 | rehabilitation therapy | TherapeuticOrPreventiveProcedure | 185 | 207 | preserve | 229-235 | 229-235 | T12 | stroke | DiseaseOrSyndrome | 229 | 235 | A4 | The purpose of this prospective study was to investigate the influence of rehabilitation therapy on the prognosis for stroke patients. | 105-245 | 105 | 245 | The purpose of this prospective study was to investigate the influence of @SUBJECT$ on the prognosis @PREDICAT$ @OBJECT$ patients. |
Fact | preserve | 57-60 | 57-60 | T7 | for | TREATS | 57 | 60 | preserve | 17-39 | 32-39 | T1 | rehabilitation therapy | TherapeuticOrPreventiveProcedure | 17 | 39 | preserve | 68-76 | 68-76 | T3 | patients | PatientOrDisabledGroup | 68 | 76 | A5 | The influence of rehabilitation therapy on the prognosis for stroke patients--a preliminary study. | 0-104 | 0 | 104 | The influence of @SUBJECT$ on the prognosis @PREDICAT$ stroke @OBJECT$ --a preliminary study. |
Fact | preserve | 61-76 | 68-76 | T6 | stroke patients | PROCESS_OF | 61 | 76 | preserve | 61-67 | 61-67 | T2 | stroke | DiseaseOrSyndrome | 61 | 67 | preserve | 68-76 | 68-76 | T3 | patients | PatientOrDisabledGroup | 68 | 76 | A6 | The influence of rehabilitation therapy on the prognosis for stroke patients--a preliminary study. | 0-104 | 0 | 104 | The influence of rehabilitation therapy on the prognosis for @SUBJECT$ @PREDICAT$ @OBJECT$ --a preliminary study. |
Fact | preserve | 57-60 | 57-60 | T7 | for | TREATS | 57 | 60 | preserve | 17-39 | 32-39 | T1 | rehabilitation therapy | TherapeuticOrPreventiveProcedure | 17 | 39 | preserve | 61-67 | 61-67 | T2 | stroke | DiseaseOrSyndrome | 61 | 67 | A7 | The influence of rehabilitation therapy on the prognosis for stroke patients--a preliminary study. | 0-104 | 0 | 104 | The influence of @SUBJECT$ on the prognosis @PREDICAT$ @OBJECT$ patients--a preliminary study. |
Uncommitted | preserve | 225-228 | 225-228 | T15 | for | TREATS | 225 | 228 | preserve | 185-207 | 200-207 | T11 | rehabilitation therapy | TherapeuticOrPreventiveProcedure | 185 | 207 | preserve | 236-244 | 236-244 | T13 | patients | PatientOrDisabledGroup | 236 | 244 | A8 | The purpose of this prospective study was to investigate the influence of rehabilitation therapy on the prognosis for stroke patients. | 105-245 | 105 | 245 | The purpose of this prospective study was to investigate the influence of @SUBJECT$ on the prognosis @PREDICAT$ stroke @OBJECT$ . |
Fact | preserve | 1921-1923 | 1921-1923 | T113 | in | COEXISTS_WITH | 1,921 | 1,923 | preserve | 1880-1887 | 1880-1887 | T104 | epitope | ImmunologicFactor | 1,880 | 1,887 | preserve | 1934-1938 | 1934-1938 | T106 | DRB1 | GeneOrGenome | 1,934 | 1,938 | A1 | Seropositive RA fraction was related to either number of shared epitope alleles (0, 1, or 2) represented in the DRB1 genotype, or, alternatively, to the combination of sex with shared epitope DRB1 genotype. | 1810-2034 | 1,810 | 2,034 | Seropositive RA fraction was related to either number of shared @SUBJECT$ alleles (0, 1, or 2) represented @PREDICAT$ the @OBJECT$ genotype, or, alternatively, to the combination of sex with shared epitope DRB1 genotype. |
Fact | preserve | 307-319 | 317-319 | T21 | Caucasian RA | PROCESS_OF | 307 | 319 | preserve | 317-319 | 317-319 | T17 | RA | DiseaseOrSyndrome | 317 | 319 | preserve | 307-316 | 307-316 | T16 | Caucasian | PopulationGroup | 307 | 316 | A3 | METHODS: We performed polymerase chain reaction based DRB1 and tumor necrosis factor (TNF) genotyping of 309 Caucasian RA and 283 Caucasian control subjects. | 192-361 | 192 | 361 | METHODS: We performed polymerase chain reaction based DRB1 and tumor necrosis factor (TNF) genotyping of 309 @OBJECT$ @PREDICAT$ @SUBJECT$ and 283 Caucasian control subjects. |
Probable | preserve | 1764-1774 | 1764-1774 | T101 | influenced | ASSOCIATED_WITH | 1,764 | 1,774 | preserve | 1730-1734 | 1730-1734 | T97 | DRB1 | GeneOrGenome | 1,730 | 1,734 | preserve | 1793-1808 | 1806-1808 | T100 | seropositive RA | DiseaseOrSyndrome | 1,793 | 1,808 | A4 | Analyses also suggested that shared epitope DRB1 genotype significantly influenced the occurrence of seropositive RA. | 1686-1809 | 1,686 | 1,809 | Analyses also suggested that shared epitope @SUBJECT$ genotype significantly @PREDICAT$ the occurrence of @OBJECT$ . |
Fact | preserve | 570-574 | 570-574 | T36 | with | PROCESS_OF | 570 | 574 | preserve | 575-591 | 581-591 | T33 | major depression | MentalOrBehavioralDysfunction | 575 | 591 | preserve | 558-569 | 558-569 | T32 | outpatients | PatientOrDisabledGroup | 558 | 569 | A1 | METHODS: The relationship between PBI scores and 4-month outcomes after treatment with antidepressants was explored in 60 outpatients with major depression, controlling for potentially confounding factors. | 430-647 | 430 | 647 | METHODS: The relationship between PBI scores and 4-month outcomes after treatment with antidepressants was explored in 60 @OBJECT$ @PREDICAT$ @SUBJECT$ , controlling for potentially confounding factors. |
Fact | preserve | 72-76 | 72-76 | T7 | with | PROCESS_OF | 72 | 76 | preserve | 83-99 | 89-99 | T5 | major depression | MentalOrBehavioralDysfunction | 83 | 99 | preserve | 63-71 | 63-71 | T4 | patients | PatientOrDisabledGroup | 63 | 71 | A2 | Perceived parenting pattern and response to antidepressants in patients with major depression. | 0-100 | 0 | 100 | Perceived parenting pattern and response to antidepressants in @OBJECT$ @PREDICAT$ @SUBJECT$ . |
Uncommitted | preserve | 60-62 | 60-62 | T6 | in | PROCESS_OF | 60 | 62 | preserve | 32-40 | 32-40 | T2 | response | ClinicalAttribute | 32 | 40 | preserve | 63-71 | 63-71 | T4 | patients | PatientOrDisabledGroup | 63 | 71 | A3 | Perceived parenting pattern and response to antidepressants in patients with major depression. | 0-100 | 0 | 100 | Perceived parenting pattern and @SUBJECT$ to antidepressants @PREDICAT$ @OBJECT$ with major depression. |
Fact | preserve | 518-522 | 518-522 | T35 | with | USES | 518 | 522 | preserve | 502-511 | 502-511 | T30 | treatment | TherapeuticOrPreventiveProcedure | 502 | 511 | preserve | 523-538 | 523-538 | T31 | antidepressants | PharmacologicSubstance | 523 | 538 | A4 | METHODS: The relationship between PBI scores and 4-month outcomes after treatment with antidepressants was explored in 60 outpatients with major depression, controlling for potentially confounding factors. | 430-647 | 430 | 647 | METHODS: The relationship between PBI scores and 4-month outcomes after @SUBJECT$ @PREDICAT$ @OBJECT$ was explored in 60 outpatients with major depression, controlling for potentially confounding factors. |
Fact | preserve | 1334-1338 | 1334-1338 | T77 | with | USES | 1,334 | 1,338 | preserve | 1324-1333 | 1324-1333 | T74 | treatment | TherapeuticOrPreventiveProcedure | 1,324 | 1,333 | preserve | 1354-1369 | 1354-1369 | T76 | antidepressants | PharmacologicSubstance | 1,354 | 1,369 | A5 | CONCLUSION: The results suggest that low levels of paternal care may be an independent predictor of a poor response to treatment with adequate antidepressants. | 1198-1370 | 1,198 | 1,370 | CONCLUSION: The results suggest that low levels of paternal care may be an independent predictor of a poor response to @SUBJECT$ @PREDICAT$ adequate @OBJECT$ . |
Probable | preserve | 1581-1585 | 1581-1585 | T90 | lead | CAUSES | 1,581 | 1,585 | preserve | 1532-1541 | 1532-1541 | T80 | dyspepsia | DiseaseOrSyndrome | 1,532 | 1,541 | preserve | 1589-1604 | 1589-1604 | T83 | hospitalisation | HealthCareActivity | 1,589 | 1,604 | A1 | NSAID-induced gastrointestinal events, ranging from dyspepsia to severe complications that can lead to hospitalisation, surgery and death, are reported more commonly than adverse effects from any other class of drugs. | 1480-1709 | 1,480 | 1,709 | NSAID-induced gastrointestinal events, ranging from @SUBJECT$ to severe complications that can @PREDICAT$ to @OBJECT$ , surgery and death, are reported more commonly than adverse effects from any other class of drugs. |
Probable | preserve | 1581-1585 | 1581-1585 | T90 | lead | CAUSES | 1,581 | 1,585 | preserve | 1532-1541 | 1532-1541 | T80 | dyspepsia | DiseaseOrSyndrome | 1,532 | 1,541 | preserve | 1618-1623 | 1618-1623 | T85 | death | OrganismFunction | 1,618 | 1,623 | A2 | NSAID-induced gastrointestinal events, ranging from dyspepsia to severe complications that can lead to hospitalisation, surgery and death, are reported more commonly than adverse effects from any other class of drugs. | 1480-1709 | 1,480 | 1,709 | NSAID-induced gastrointestinal events, ranging from @SUBJECT$ to severe complications that can @PREDICAT$ to hospitalisation, surgery and @OBJECT$ , are reported more commonly than adverse effects from any other class of drugs. |
Fact | preserve | 1088-1095 | 1088-1095 | T60 | control | TREATS | 1,088 | 1,095 | preserve | 1039-1045 | 1039-1045 | T51 | NSAIDs | PharmacologicSubstance | 1,039 | 1,045 | preserve | 1099-1119 | 1115-1119 | T55 | musculoskeletal pain | SignOrSymptom | 1,099 | 1,119 | A3 | NSAIDs are highly effective agents for the control of musculoskeletal pain and inflammation, and as such are among the most widely used drugs worldwide. | 1039-1203 | 1,039 | 1,203 | @SUBJECT$ are highly effective agents for the @PREDICAT$ of @OBJECT$ and inflammation, and as such are among the most widely used drugs worldwide. |
Fact | preserve | 1313-1322 | 1313-1322 | T67 | receiving | ADMINISTERED_TO | 1,313 | 1,322 | preserve | 1323-1329 | 1323-1329 | T66 | NSAIDs | PharmacologicSubstance | 1,323 | 1,329 | preserve | 1298-1306 | 1298-1306 | T65 | patients | PatientOrDisabledGroup | 1,298 | 1,306 | A5 | It is well recognised that marked improvements in quality of life occur among arthritic patients receiving NSAIDs. | 1204-1330 | 1,204 | 1,330 | It is well recognised that marked improvements in quality of life occur among arthritic @OBJECT$ @PREDICAT$ @SUBJECT$ . |
Fact | preserve | 2323-2346 | 2335-2346 | T124 | misoprostol prophylaxis | USES | 2,323 | 2,346 | preserve | 2335-2346 | 2335-2346 | T119 | prophylaxis | TherapeuticOrPreventiveProcedure | 2,335 | 2,346 | preserve | 2323-2334 | 2323-2334 | T118 | misoprostol | Eicosanoid | 2,323 | 2,334 | A8 | Therefore, the widespread use of misoprostol prophylaxis not only has important economic consequences, but has important consequences for quality of life. | 2284-2451 | 2,284 | 2,451 | Therefore, the widespread use of @OBJECT$ @PREDICAT$ @SUBJECT$ not only has important economic consequences, but has important consequences for quality of life. |
Fact | preserve | 1088-1095 | 1088-1095 | T60 | control | TREATS | 1,088 | 1,095 | preserve | 1039-1045 | 1039-1045 | T51 | NSAIDs | PharmacologicSubstance | 1,039 | 1,045 | preserve | 1124-1136 | 1124-1136 | T56 | inflammation | PathologicFunction | 1,124 | 1,136 | A9 | NSAIDs are highly effective agents for the control of musculoskeletal pain and inflammation, and as such are among the most widely used drugs worldwide. | 1039-1203 | 1,039 | 1,203 | @SUBJECT$ are highly effective agents for the @PREDICAT$ of musculoskeletal pain and @OBJECT$ , and as such are among the most widely used drugs worldwide. |
Fact | preserve | 1944-1946 | 1944-1946 | T118 | in | PROCESS_OF | 1,944 | 1,946 | preserve | 1937-1943 | 1937-1943 | T98 | stroke | DiseaseOrSyndrome | 1,937 | 1,943 | preserve | 1951-1957 | 1951-1957 | T99 | gerbil | Mammal | 1,951 | 1,957 | A1 | Indeed, the worsening of stroke in the gerbil after incomplete ligation of the carotid by pre-treatment with ACEI had been demonstrated by these authors (J Cerebral Blood Flow Metab, 1988; 24:937), and they further show that pre-administration of losartan significantly reduced the ischemic brain damage and the mortality induced by the abrupt ligation of one carotid, but that this preventive effect of losartan was abolished if enalapril was co-administrated (J Cardiovasc Pharmacol 1994; 24:937). | 1912-2448 | 1,912 | 2,448 | Indeed, the worsening of @SUBJECT$ @PREDICAT$ the @OBJECT$ after incomplete ligation of the carotid by pre-treatment with ACEI had been demonstrated by these authors (J Cerebral Blood Flow Metab, 1988; 24:937), and they further show that pre-administration of losartan significantly reduced the ischemic brain damage and the mortality induced by the abrupt ligation of one carotid, but that this preventive effect of losartan was abolished if enalapril was co-administrated (J Cardiovasc Pharmacol 1994; 24:937). |
Fact | preserve | 1033-1040 | 1033-1040 | T56 | prevent | PREVENTS | 1,033 | 1,040 | preserve | 994-1001 | 994-1001 | T52 | therapy | TherapeuticOrPreventiveProcedure | 994 | 1,001 | preserve | 1041-1047 | 1041-1047 | T55 | stroke | DiseaseOrSyndrome | 1,041 | 1,047 | A4 | Nonetheless, these results suggest that for a similar blood pressure lowering effect, conventional therapy is more effective than ACEI to prevent stroke. | 889-1048 | 889 | 1,048 | Nonetheless, these results suggest that for a similar blood pressure lowering effect, conventional @SUBJECT$ is more effective than ACEI to @PREDICAT$ @OBJECT$ . |
Fact | preserve | 355-357 | 355-357 | T26 | in | PROCESS_OF | 355 | 357 | preserve | 329-335 | 329-335 | T18 | stroke | DiseaseOrSyndrome | 329 | 335 | preserve | 358-366 | 358-366 | T20 | patients | PatientOrDisabledGroup | 358 | 366 | A7 | In contrast with the expected results, the Captopril Prevention Project study has found that the relative risk of stroke was greater by 25% in patients treated with ACEI than in patients receiving the conventional diuretics +/- betablockers regimen (Hanson et al. ISH Amsterdam, June 98). | 209-516 | 209 | 516 | In contrast with the expected results, the Captopril Prevention Project study has found that the relative risk of @SUBJECT$ was greater by 25% @PREDICAT$ @OBJECT$ treated with ACEI than in patients receiving the conventional diuretics +/- betablockers regimen (Hanson et al. ISH Amsterdam, June 98). |
Fact | preserve | 408-417 | 408-417 | T27 | receiving | ADMINISTERED_TO | 408 | 417 | preserve | 469-476 | 469-476 | T24 | regimen | ResearchActivity | 469 | 476 | preserve | 399-407 | 399-407 | T21 | patients | PatientOrDisabledGroup | 399 | 407 | A10 | In contrast with the expected results, the Captopril Prevention Project study has found that the relative risk of stroke was greater by 25% in patients treated with ACEI than in patients receiving the conventional diuretics +/- betablockers regimen (Hanson et al. ISH Amsterdam, June 98). | 209-516 | 209 | 516 | In contrast with the expected results, the Captopril Prevention Project study has found that the relative risk of stroke was greater by 25% in patients treated with ACEI than in @OBJECT$ @PREDICAT$ the conventional diuretics +/- betablockers @SUBJECT$ (Hanson et al. ISH Amsterdam, June 98). |
Fact | preserve | 1196-1202 | 1196-1202 | T66 | reduce | PREVENTS | 1,196 | 1,202 | preserve | 1172-1192 | 1183-1192 | T63 | preventive treatment | TherapeuticOrPreventiveProcedure | 1,172 | 1,192 | preserve | 1203-1233 | 1224-1233 | T64 | cardiovascular morbidity | DiseaseOrSyndrome | 1,203 | 1,233 | A12 | This finding, in discrepancy with the current prevailing opinion that ACEI have emerged as the most effective preventive treatment to reduce cardiovascular morbidity, is regarded as surprising by the investigators. | 1049-1282 | 1,049 | 1,282 | This finding, in discrepancy with the current prevailing opinion that ACEI have emerged as the most effective @SUBJECT$ to @PREDICAT$ @OBJECT$ , is regarded as surprising by the investigators. |
Fact | preserve | 898-902 | 898-902 | T71 | with | PART_OF | 898 | 902 | preserve | 922-925 | 922-925 | T63 | IRA | BodyPartOrganOrOrganComponent | 922 | 925 | preserve | 889-897 | 889-897 | T59 | patients | PatientOrDisabledGroup | 889 | 897 | A1 | Group I consisted in patients with a totally occluded IRA (n = 10), and group II consisted in patients with a patent, though stenosed, IRA (n = 21). | 868-1023 | 868 | 1,023 | Group I consisted in @OBJECT$ @PREDICAT$ a totally occluded @SUBJECT$ (n = 10), and group II consisted in patients with a patent, though stenosed, IRA (n = 21). |
Fact | preserve | 589-616 | 608-616 | T53 | asymptomatic patients | PROCESS_OF | 589 | 616 | preserve | 589-601 | 589-601 | T37 | asymptomatic | Finding | 589 | 601 | preserve | 608-616 | 608-616 | T38 | patients | PatientOrDisabledGroup | 608 | 616 | A2 | METHODS: We prospectively studied 31 consecutive asymptomatic patients (aged 57 +/- 2 years, 24 with anterior infarcts) after Q-wave myocardial infarction with > or = 70% stenosis of the infarct-related artery (IRA) who underwent early elective revascularization (days 4-10 after myocardial infarction). | 540-867 | 540 | 867 | METHODS: We prospectively studied 31 consecutive @SUBJECT$ @PREDICAT$ @OBJECT$ (aged 57 +/- 2 years, 24 with anterior infarcts) after Q-wave myocardial infarction with > or = 70% stenosis of the infarct-related artery (IRA) who underwent early elective revascularization (days 4-10 after myocardial infarction). |
Fact | preserve | 2517-2538 | 2530-2538 | T162 | asymptomatic patients | PROCESS_OF | 2,517 | 2,538 | preserve | 2517-2529 | 2517-2529 | T148 | asymptomatic | Finding | 2,517 | 2,529 | preserve | 2530-2538 | 2530-2538 | T149 | patients | PatientOrDisabledGroup | 2,530 | 2,538 | A3 | CONCLUSION: There is less global left ventricular remodeling, a potentially deleterious process, after elective revascularization early after Q-wave myocardial infarction in asymptomatic patients who had had a totally occluded IRA before revascularization than there is in patients who had already had a patent, though stenosed, IRA before revascularization. | 2331-2713 | 2,331 | 2,713 | CONCLUSION: There is less global left ventricular remodeling, a potentially deleterious process, after elective revascularization early after Q-wave myocardial infarction in @SUBJECT$ @PREDICAT$ @OBJECT$ who had had a totally occluded IRA before revascularization than there is in patients who had already had a patent, though stenosed, IRA before revascularization. |
Fact | preserve | 732-734 | 732-734 | T54 | of | LOCATION_OF | 732 | 734 | preserve | 755-761 | 755-761 | T47 | artery | BodyPartOrganOrOrganComponent | 755 | 761 | preserve | 723-731 | 723-731 | T44 | stenosis | PathologicFunction | 723 | 731 | A4 | METHODS: We prospectively studied 31 consecutive asymptomatic patients (aged 57 +/- 2 years, 24 with anterior infarcts) after Q-wave myocardial infarction with > or = 70% stenosis of the infarct-related artery (IRA) who underwent early elective revascularization (days 4-10 after myocardial infarction). | 540-867 | 540 | 867 | METHODS: We prospectively studied 31 consecutive asymptomatic patients (aged 57 +/- 2 years, 24 with anterior infarcts) after Q-wave myocardial infarction with > or = 70% @OBJECT$ @PREDICAT$ the infarct-related @SUBJECT$ (IRA) who underwent early elective revascularization (days 4-10 after myocardial infarction). |
Fact | preserve | 307-311 | 307-311 | T25 | with | PART_OF | 307 | 311 | preserve | 347-353 | 347-353 | T22 | artery | BodyPartOrganOrOrganComponent | 347 | 353 | preserve | 281-289 | 281-289 | T18 | patients | PatientOrDisabledGroup | 281 | 289 | A6 | BACKGROUND: Patients with angina after a Q-wave myocardial infarction benefit from elective revascularization, but it is not known whether asymptomatic patients, including those with a totally occluded infarct-related artery, improve after revascularization. | 117-393 | 117 | 393 | BACKGROUND: Patients with angina after a Q-wave myocardial infarction benefit from elective revascularization, but it is not known whether asymptomatic @OBJECT$ , including those @PREDICAT$ a totally occluded infarct-related @SUBJECT$ , improve after revascularization. |
Fact | preserve | 2514-2516 | 2514-2516 | T163 | in | PROCESS_OF | 2,514 | 2,516 | preserve | 2492-2513 | 2503-2513 | T147 | myocardial infarction | DiseaseOrSyndrome | 2,492 | 2,513 | preserve | 2530-2538 | 2530-2538 | T149 | patients | PatientOrDisabledGroup | 2,530 | 2,538 | A7 | CONCLUSION: There is less global left ventricular remodeling, a potentially deleterious process, after elective revascularization early after Q-wave myocardial infarction in asymptomatic patients who had had a totally occluded IRA before revascularization than there is in patients who had already had a patent, though stenosed, IRA before revascularization. | 2331-2713 | 2,331 | 2,713 | CONCLUSION: There is less global left ventricular remodeling, a potentially deleterious process, after elective revascularization early after Q-wave @SUBJECT$ @PREDICAT$ asymptomatic @OBJECT$ who had had a totally occluded IRA before revascularization than there is in patients who had already had a patent, though stenosed, IRA before revascularization. |
Fact | preserve | 480-501 | 493-501 | T35 | asymptomatic patients | PROCESS_OF | 480 | 501 | preserve | 480-492 | 480-492 | T31 | asymptomatic | Finding | 480 | 492 | preserve | 493-501 | 493-501 | T32 | patients | PatientOrDisabledGroup | 493 | 501 | A8 | OBJECTIVE: To determine the effect of early postinfarction revascularization of asymptomatic patients on left ventricular remodeling. | 394-539 | 394 | 539 | OBJECTIVE: To determine the effect of early postinfarction revascularization of @SUBJECT$ @PREDICAT$ @OBJECT$ on left ventricular remodeling. |
Uncommitted | preserve | 422-428 | 422-428 | T34 | effect | AFFECTS | 422 | 428 | preserve | 459-476 | 459-476 | T30 | revascularization | TherapeuticOrPreventiveProcedure | 459 | 476 | preserve | 505-538 | 528-538 | T33 | left ventricular remodeling | OrganOrTissueFunction | 505 | 538 | A9 | OBJECTIVE: To determine the effect of early postinfarction revascularization of asymptomatic patients on left ventricular remodeling. | 394-539 | 394 | 539 | OBJECTIVE: To determine the @PREDICAT$ of early postinfarction @SUBJECT$ of asymptomatic patients on @OBJECT$ . |
Fact | preserve | 56-77 | 69-77 | T9 | asymptomatic patients | PROCESS_OF | 56 | 77 | preserve | 56-68 | 56-68 | T5 | asymptomatic | Finding | 56 | 68 | preserve | 69-77 | 69-77 | T6 | patients | PatientOrDisabledGroup | 69 | 77 | A10 | The effect of early postinfarction revascularization of asymptomatic patients on left ventricular remodeling. | 0-116 | 0 | 116 | The effect of early postinfarction revascularization of @SUBJECT$ @PREDICAT$ @OBJECT$ on left ventricular remodeling. |
Fact | preserve | 2843-2864 | 2856-2864 | T174 | asymptomatic patients | PROCESS_OF | 2,843 | 2,864 | preserve | 2843-2855 | 2843-2855 | T172 | asymptomatic | Finding | 2,843 | 2,855 | preserve | 2856-2864 | 2856-2864 | T173 | patients | PatientOrDisabledGroup | 2,856 | 2,864 | A11 | These results suggest that restoration of patency of IRA after a Q-wave myocardial infarction is beneficial even for asymptomatic patients. | 2714-2865 | 2,714 | 2,865 | These results suggest that restoration of patency of IRA after a Q-wave myocardial infarction is beneficial even for @SUBJECT$ @PREDICAT$ @OBJECT$ . |
Fact | preserve | 4-10 | 4-10 | T8 | effect | AFFECTS | 4 | 10 | preserve | 35-52 | 35-52 | T4 | revascularization | TherapeuticOrPreventiveProcedure | 35 | 52 | preserve | 88-115 | 105-115 | T7 | left ventricular remodeling | OrganOrTissueFunction | 88 | 115 | A13 | The effect of early postinfarction revascularization of asymptomatic patients on left ventricular remodeling. | 0-116 | 0 | 116 | The @PREDICAT$ of early postinfarction @SUBJECT$ of asymptomatic patients on @OBJECT$ . |
Fact | preserve | 1062-1089 | 1073-1089 | T83 | dobutamine echocardiography | USES | 1,062 | 1,089 | preserve | 1073-1089 | 1073-1089 | T76 | echocardiography | DiagnosticProcedure | 1,073 | 1,089 | preserve | 1062-1072 | 1062-1072 | T75 | dobutamine | OrganicChemical | 1,062 | 1,072 | A14 | Resting echocardiography and low-dose dobutamine echocardiography were performed at baseline (day 3 +/- 1), and rest echocardiography was repeated after an 8-week follow-up. | 1024-1210 | 1,024 | 1,210 | Resting echocardiography and low-dose @OBJECT$ @PREDICAT$ @SUBJECT$ were performed at baseline (day 3 +/- 1), and rest echocardiography was repeated after an 8-week follow-up. |
Fact | preserve | 262-289 | 281-289 | T24 | asymptomatic patients | PROCESS_OF | 262 | 289 | preserve | 262-274 | 262-274 | T17 | asymptomatic | Finding | 262 | 274 | preserve | 281-289 | 281-289 | T18 | patients | PatientOrDisabledGroup | 281 | 289 | A15 | BACKGROUND: Patients with angina after a Q-wave myocardial infarction benefit from elective revascularization, but it is not known whether asymptomatic patients, including those with a totally occluded infarct-related artery, improve after revascularization. | 117-393 | 117 | 393 | BACKGROUND: Patients with angina after a Q-wave myocardial infarction benefit from elective revascularization, but it is not known whether @SUBJECT$ @PREDICAT$ @OBJECT$ , including those with a totally occluded infarct-related artery, improve after revascularization. |
Fact | preserve | 2064-2067 | 2064-2067 | T134 | for | TREATS | 2,064 | 2,067 | preserve | 2054-2063 | 2054-2063 | T128 | follow-up | HealthCareActivity | 2,054 | 2,063 | preserve | 2068-2076 | 2068-2076 | T129 | patients | PatientOrDisabledGroup | 2,068 | 2,076 | A19 | Similarly, the left ventricular end-diastolic volume index had decreased by 0.7 +/- 2.4 ml/m2 versus baseline at follow-up for patients in group I and increased by 7.8 +/- 2.1 ml/m2 for patients in group II (P = 0.02). | 1928-2165 | 1,928 | 2,165 | Similarly, the left ventricular end-diastolic volume index had decreased by 0.7 +/- 2.4 ml/m2 versus baseline at @SUBJECT$ @PREDICAT$ @OBJECT$ in group I and increased by 7.8 +/- 2.1 ml/m2 for patients in group II (P = 0.02). |
Fact | preserve | 731-735 | 731-735 | T47 | with | PROCESS_OF | 731 | 735 | preserve | 736-756 | 747-756 | T37 | rheumatoid arthritis | DiseaseOrSyndrome | 736 | 756 | preserve | 722-730 | 722-730 | T36 | patients | PatientOrDisabledGroup | 722 | 730 | A1 | The combination of sulfasalazine, methotrexate with reducing high-dose prednisolone, is demonstrated to be cost-effective in patients with rheumatoid arthritis, but although several other combinations have been reported effective in patients with rheumatoid arthritis, most trials do not have the power to provide a definitive answer as to the best combination available, if one exists. | 470-887 | 470 | 887 | The combination of sulfasalazine, methotrexate with reducing high-dose prednisolone, is demonstrated to be cost-effective in patients with rheumatoid arthritis, but although several other combinations have been reported effective in @OBJECT$ @PREDICAT$ @SUBJECT$ , most trials do not have the power to provide a definitive answer as to the best combination available, if one exists. |
Fact | preserve | 610-614 | 610-614 | T46 | with | PROCESS_OF | 610 | 614 | preserve | 621-641 | 632-641 | T32 | rheumatoid arthritis | DiseaseOrSyndrome | 621 | 641 | preserve | 601-609 | 601-609 | T31 | patients | PatientOrDisabledGroup | 601 | 609 | A4 | The combination of sulfasalazine, methotrexate with reducing high-dose prednisolone, is demonstrated to be cost-effective in patients with rheumatoid arthritis, but although several other combinations have been reported effective in patients with rheumatoid arthritis, most trials do not have the power to provide a definitive answer as to the best combination available, if one exists. | 470-887 | 470 | 887 | The combination of sulfasalazine, methotrexate with reducing high-dose prednisolone, is demonstrated to be cost-effective in @OBJECT$ @PREDICAT$ @SUBJECT$ , but although several other combinations have been reported effective in patients with rheumatoid arthritis, most trials do not have the power to provide a definitive answer as to the best combination available, if one exists. |
Fact | preserve | 107-111 | 107-111 | T10 | with | PROCESS_OF | 107 | 111 | preserve | 118-138 | 129-138 | T6 | rheumatoid arthritis | DiseaseOrSyndrome | 118 | 138 | preserve | 98-106 | 98-106 | T5 | patients | PatientOrDisabledGroup | 98 | 106 | A6 | Rheumatologists now seem to accept that early treatment of patients with rheumatoid arthritis with disease-modifying antirheumatic drugs is required if erosions are to be prevented. | 39-232 | 39 | 232 | Rheumatologists now seem to accept that early treatment of @OBJECT$ @PREDICAT$ @SUBJECT$ with disease-modifying antirheumatic drugs is required if erosions are to be prevented. |
Probable | preserve | 85-94 | 85-94 | T9 | treatment | TREATS | 85 | 94 | preserve | 144-181 | 176-181 | T7 | disease-modifying antirheumatic drugs | PharmacologicSubstance | 144 | 181 | preserve | 98-106 | 98-106 | T5 | patients | PatientOrDisabledGroup | 98 | 106 | A7 | Rheumatologists now seem to accept that early treatment of patients with rheumatoid arthritis with disease-modifying antirheumatic drugs is required if erosions are to be prevented. | 39-232 | 39 | 232 | Rheumatologists now seem to accept that early @PREDICAT$ of @OBJECT$ with rheumatoid arthritis with @SUBJECT$ is required if erosions are to be prevented. |
Probable | preserve | 85-94 | 85-94 | T9 | treatment | TREATS | 85 | 94 | preserve | 144-181 | 176-181 | T7 | disease-modifying antirheumatic drugs | PharmacologicSubstance | 144 | 181 | preserve | 118-138 | 129-138 | T6 | rheumatoid arthritis | DiseaseOrSyndrome | 118 | 138 | A8 | Rheumatologists now seem to accept that early treatment of patients with rheumatoid arthritis with disease-modifying antirheumatic drugs is required if erosions are to be prevented. | 39-232 | 39 | 232 | Rheumatologists now seem to accept that early @PREDICAT$ of patients with @OBJECT$ with @SUBJECT$ is required if erosions are to be prevented. |
Fact | preserve | 474-485 | 474-485 | T44 | combination | COEXISTS_WITH | 474 | 485 | preserve | 504-516 | 504-516 | T26 | methotrexate | OrganicChemical | 504 | 516 | preserve | 489-502 | 489-502 | T25 | sulfasalazine | OrganicChemical | 489 | 502 | A9 | The combination of sulfasalazine, methotrexate with reducing high-dose prednisolone, is demonstrated to be cost-effective in patients with rheumatoid arthritis, but although several other combinations have been reported effective in patients with rheumatoid arthritis, most trials do not have the power to provide a definitive answer as to the best combination available, if one exists. | 470-887 | 470 | 887 | The @PREDICAT$ of @OBJECT$ , @SUBJECT$ with reducing high-dose prednisolone, is demonstrated to be cost-effective in patients with rheumatoid arthritis, but although several other combinations have been reported effective in patients with rheumatoid arthritis, most trials do not have the power to provide a definitive answer as to the best combination available, if one exists. |
Probable | preserve | 452-462 | 452-462 | T27 | contribute | PREDISPOSES | 452 | 462 | preserve | 265-277 | 265-277 | T18 | leukotrienes | BiologicallyActiveSubstance | 265 | 277 | preserve | 466-484 | 473-484 | T26 | airway obstruction | DiseaseOrSyndrome | 466 | 484 | A3 | The leukotrienes were discovered in basic studies of arachidonic acid metabolism in leucocytes 20 years ago and were found to display a number of biological activities which may contribute to airway obstruction. | 261-485 | 261 | 485 | The @SUBJECT$ were discovered in basic studies of arachidonic acid metabolism in leucocytes 20 years ago and were found to display a number of biological activities which may @PREDICAT$ to @OBJECT$ . |
Fact | preserve | 875-882 | 875-882 | T53 | therapy | TREATS | 875 | 882 | preserve | 821-837 | 821-837 | T48 | antileukotrienes | OrganicChemical | 821 | 837 | preserve | 886-892 | 886-892 | T52 | asthma | DiseaseOrSyndrome | 886 | 892 | A4 | Moreover, treatment trials have established that this new class of drugs has beneficial anti-asthmatic properties, and several antileukotrienes have recently been introduced as new therapy of asthma. | 682-893 | 682 | 893 | Moreover, treatment trials have established that this new class of drugs has beneficial anti-asthmatic properties, and several @SUBJECT$ have recently been introduced as new @PREDICAT$ of @OBJECT$ . |
Fact | preserve | 73-94 | 89-94 | T15 | Antileukotriene drugs | ISA | 73 | 94 | preserve | 73-88 | 73-88 | T6 | Antileukotriene | OrganicChemical | 73 | 88 | preserve | 89-94 | 89-94 | T7 | drugs | PharmacologicSubstance | 89 | 94 | A7 | Antileukotriene drugs inhibit the formation or action of leukotrienes, which are potent lipid mediators generated from arachidonic acid in lung tissue and inflammatory cells. | 73-260 | 73 | 260 | @SUBJECT$ @PREDICAT$ @OBJECT$ inhibit the formation or action of leukotrienes, which are potent lipid mediators generated from arachidonic acid in lung tissue and inflammatory cells. |
Fact | preserve | 508-529 | 524-529 | T38 | antileukotriene drugs | ISA | 508 | 529 | preserve | 508-523 | 508-523 | T29 | antileukotriene | OrganicChemical | 508 | 523 | preserve | 524-529 | 524-529 | T30 | drugs | PharmacologicSubstance | 524 | 529 | A9 | Clinical studies with antileukotriene drugs have indeed demonstrated that leukotrienes are significant mediators of airway obstruction evoked by many common trigger factors in asthma. | 486-681 | 486 | 681 | Clinical studies with @SUBJECT$ @PREDICAT$ @OBJECT$ have indeed demonstrated that leukotrienes are significant mediators of airway obstruction evoked by many common trigger factors in asthma. |
Fact | preserve | 1184-1194 | 1191-1194 | T84 | ostial RAS | LOCATION_OF | 1,184 | 1,194 | preserve | 1184-1190 | 1184-1190 | T73 | ostial | BodySpaceOrJunction | 1,184 | 1,190 | preserve | 1191-1194 | 1191-1194 | T74 | RAS | DiseaseOrSyndrome | 1,191 | 1,194 | A1 | Several prospective studies dealing with renal artery stenting in ostial RAS found that the implantation of endoprostheses leads to much better morphologic longterm results as compared to those of balloon angioplasty alone and may be a safe and effective alternative to surgery. | 1112-1408 | 1,112 | 1,408 | Several prospective studies dealing with renal artery stenting in @SUBJECT$ @PREDICAT$ @OBJECT$ found that the implantation of endoprostheses leads to much better morphologic longterm results as compared to those of balloon angioplasty alone and may be a safe and effective alternative to surgery. |
Fact | preserve | 908-910 | 908-910 | T59 | in | TREATS | 908 | 910 | preserve | 854-873 | 862-873 | T54 | balloon angioplasty | TherapeuticOrPreventiveProcedure | 854 | 873 | preserve | 947-954 | 947-954 | T58 | disease | DiseaseOrSyndrome | 947 | 954 | A2 | However, there is continuous discussion concerning the utility of balloon angioplasty and renal stenting, respectively, in patients with atherosclerotic disease. | 782-955 | 782 | 955 | However, there is continuous discussion concerning the utility of @SUBJECT$ and renal stenting, respectively, @PREDICAT$ patients with atherosclerotic @OBJECT$ . |
Possible | preserve | 495-504 | 495-504 | T35 | treatment | TREATS | 495 | 504 | preserve | 454-466 | 454-466 | T26 | implantation | TherapeuticOrPreventiveProcedure | 454 | 466 | preserve | 538-550 | 538-550 | T31 | hypertension | DiseaseOrSyndrome | 538 | 550 | A3 | In experienced hands renal artery revascularization with or without stent implantation may be a safe and effective treatment in patients with sustained hypertension resistant to intensive antihypertensive treatment. | 374-601 | 374 | 601 | In experienced hands renal artery revascularization with or without stent @SUBJECT$ may be a safe and effective @PREDICAT$ in patients with sustained @OBJECT$ resistant to intensive antihypertensive treatment. |
Possible | preserve | 495-504 | 495-504 | T35 | treatment | TREATS | 495 | 504 | preserve | 408-425 | 408-425 | T24 | revascularization | TherapeuticOrPreventiveProcedure | 408 | 425 | preserve | 538-550 | 538-550 | T31 | hypertension | DiseaseOrSyndrome | 538 | 550 | A4 | In experienced hands renal artery revascularization with or without stent implantation may be a safe and effective treatment in patients with sustained hypertension resistant to intensive antihypertensive treatment. | 374-601 | 374 | 601 | In experienced hands renal artery @SUBJECT$ with or without stent implantation may be a safe and effective @PREDICAT$ in patients with sustained @OBJECT$ resistant to intensive antihypertensive treatment. |
Fact | preserve | 1483-1485 | 1483-1485 | T99 | in | TREATS | 1,483 | 1,485 | preserve | 1470-1482 | 1470-1482 | T88 | implantation | TherapeuticOrPreventiveProcedure | 1,470 | 1,482 | preserve | 1486-1494 | 1486-1494 | T89 | patients | PatientOrDisabledGroup | 1,486 | 1,494 | A5 | In addition, the functional results suggest that stent implantation in patients with mild or severe renal dysfunction may slow progression of renal failure and, thus delay the need for renal replacement therapy. | 1409-1638 | 1,409 | 1,638 | In addition, the functional results suggest that stent @SUBJECT$ @PREDICAT$ @OBJECT$ with mild or severe renal dysfunction may slow progression of renal failure and, thus delay the need for renal replacement therapy. |
Fact | preserve | 908-910 | 908-910 | T59 | in | TREATS | 908 | 910 | preserve | 854-873 | 862-873 | T54 | balloon angioplasty | TherapeuticOrPreventiveProcedure | 854 | 873 | preserve | 911-919 | 911-919 | T56 | patients | PatientOrDisabledGroup | 911 | 919 | A6 | However, there is continuous discussion concerning the utility of balloon angioplasty and renal stenting, respectively, in patients with atherosclerotic disease. | 782-955 | 782 | 955 | However, there is continuous discussion concerning the utility of @SUBJECT$ and renal stenting, respectively, @PREDICAT$ @OBJECT$ with atherosclerotic disease. |
Fact | preserve | 448-466 | 454-466 | T34 | stent implantation | USES | 448 | 466 | preserve | 454-466 | 454-466 | T26 | implantation | TherapeuticOrPreventiveProcedure | 454 | 466 | preserve | 448-453 | 448-453 | T25 | stent | MedicalDevice | 448 | 453 | A7 | In experienced hands renal artery revascularization with or without stent implantation may be a safe and effective treatment in patients with sustained hypertension resistant to intensive antihypertensive treatment. | 374-601 | 374 | 601 | In experienced hands renal artery revascularization with or without @OBJECT$ @PREDICAT$ @SUBJECT$ may be a safe and effective treatment in patients with sustained hypertension resistant to intensive antihypertensive treatment. |
Fact | preserve | 517-521 | 517-521 | T37 | with | PROCESS_OF | 517 | 521 | preserve | 538-550 | 538-550 | T31 | hypertension | DiseaseOrSyndrome | 538 | 550 | preserve | 508-516 | 508-516 | T29 | patients | PatientOrDisabledGroup | 508 | 516 | A9 | In experienced hands renal artery revascularization with or without stent implantation may be a safe and effective treatment in patients with sustained hypertension resistant to intensive antihypertensive treatment. | 374-601 | 374 | 601 | In experienced hands renal artery revascularization with or without stent implantation may be a safe and effective treatment in @OBJECT$ @PREDICAT$ sustained @SUBJECT$ resistant to intensive antihypertensive treatment. |
Possible | preserve | 495-504 | 495-504 | T35 | treatment | TREATS | 495 | 504 | preserve | 408-425 | 408-425 | T24 | revascularization | TherapeuticOrPreventiveProcedure | 408 | 425 | preserve | 508-516 | 508-516 | T29 | patients | PatientOrDisabledGroup | 508 | 516 | A10 | In experienced hands renal artery revascularization with or without stent implantation may be a safe and effective treatment in patients with sustained hypertension resistant to intensive antihypertensive treatment. | 374-601 | 374 | 601 | In experienced hands renal artery @SUBJECT$ with or without stent implantation may be a safe and effective @PREDICAT$ in @OBJECT$ with sustained hypertension resistant to intensive antihypertensive treatment. |
Fact | preserve | 156-161 | 156-161 | T16 | cause | CAUSES | 156 | 161 | preserve | 109-130 | 122-130 | T8 | Renal artery stenosis | DiseaseOrSyndrome | 109 | 130 | preserve | 165-187 | 175-187 | T12 | secondary hypertension | DiseaseOrSyndrome | 165 | 187 | A11 | Renal artery stenosis (RAS) is the most common cause of secondary hypertension, with a prevalence of about 1% in the general population of people with hypertension. | 109-285 | 109 | 285 | @SUBJECT$ (RAS) is the most common @PREDICAT$ of @OBJECT$ , with a prevalence of about 1% in the general population of people with hypertension. |